Polyrizon Ltd.

Company Overview

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.



Latest Company Reports

Latest Press Releases

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

{{getFormattedDate('2024-12-02T08:02:00.0000000')}}
Loading...

Stock Snapshot

{{stockQuote.companyFullName}}
{{stockQuote.quoteInfo}}
{{stockQuote.valueFormatted}}
{{getFormattedValue(stockQuote.changesValueFormatted)}} ({{getFormattedValue(stockQuote.changesPercentFormatted)}}%)
{{getFormattedDateTime(stockQuote.delayDate)}}
{{stockQuote.onlyDateFormatted}} (At Close)
Previous Close
{{todayDetailedInformation.previousClose}}
Volume
{{todayDetailedInformation.volume}}
Today’s Open
{{todayDetailedInformation.todaysOpen}}
Average Volume (10 days)
{{detailQuote.averageVolume}}
Day's Range
{{todayDetailedInformation.todaysLow}} - {{todayDetailedInformation.todaysHigh}}
Market Cap
{{detailQuote.marketCap}}
52 Week Range
{{detailQuote.weekLow}} -{{detailQuote.weekHigh}}
Total Shares Outstanding
{{detailQuote.totalSharesOutstanding}}
More Info